Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 5 of 5 for “"LRRK2 activity"”.
-
Pre-clinical screening for re-purposed and novel compounds that reduce synucleinopathy, and investigation of LRRK2 activity and VPS35 function within human cell culture models of Parkinson’s disease
… disease mechanism. Mutations within LRRK2 are the most common cause of familial PD, where most mutations in LRRK2 increase its kinase activity. More recently a D620N mutation within VPS35, a component of the retromer complex, has been identified as an autosomal dominant cause of PD …
-
Exploring Parkinson’s disease associated LRRK2 and PINK1/Parkin signal transduction pathways within immune cells
… have genetic, familial forms of the disease2. LRRK2 and PINK1 are two independent genes that respectively cause autosomal dominant and autosomal recessive forms of PD. They both encode protein kinases, which control signal transduction pathways through reversible phosphorylation of target …
-
LEUCINE-RICH REPEAT KINASE 2 (LRRK2) AT THE CROSSROAD OF INSULIN SIGNALLING AND PARKINSON S DISEASE
Leucine-Rich Repeat Kinase 2 (LRRK2) is a large protein encompassing multiple functional domains, including kinase and GTPase enzymatic activity and several protein-protein interaction modules. It is expressed in the central nervous system (CNS) and it is among the most important genetic risk …
-
Novel Biomarkers For Parkinson Disease
… Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are known to increase LRRK2 kinase activity and increase the risk for late-onset PD. In this thesis, I discovered that LRRK2 is secreted into exosomes in urine and CSF, where LRRK2 kinase activity, reflected by autophosphorylation at …
-
Developing assays to characterize the effects of LRRK2 G2019S on axonal lysosomes
… have thus been thought to be altered in PD. LRRK2 G2019S, a gain-of-kinase-function mutation, is one of PD's most common known causative mutations, and LRRK2-specific small molecule inhibitors have been developed as possible therapeutics. However, LRRK2 G2019S is incompletely penetrant, and …